Helsinn Group
Rudy McCalebb has extensive experience in the pharmaceutical sales industry, particularly within oncology. Currently serving as a Senior Pharmaceutical Sales Representative and Senior Oncology Specialist at Helsinn Group since January 2018, McCalebb previously held a significant role in developing the Oncology Division at Daiichi Sankyo from October 2012, where responsibilities included educating healthcare providers across multiple Midwestern states. Prior to this, McCalebb worked for Quintiles as an Oncology Sales Representative, successfully launching a new compound for metastatic melanoma and exceeding sales objectives. Earlier positions included Midwest Sales Manager at Response Genetics and Associate Director at Imclone Systems, managing sales and developing diagnostic products. McCalebb's career commenced at Pfizer, where valuable expertise was gained in therapeutic specialties related to various cancers. McCalebb holds a BSBA in Business from Roosevelt University.
This person is not in any offices
Helsinn Group
1 followers
Welcome to Helsinn’s LinkedIn page. This account shall only be used to share (*) news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional Helsinn is a fully integrated, global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and an innovative pipeline of cancer therapeutics. Helsinn is a third-generation family-owned company, that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. It operates a unique licensing business model with integrated drug development and manufacturing capabilities. Helsinn has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd. If you are interested in joining Helsinn or one of our affiliates, please visit helsinn.com. Applications should only be submitted via the appropriate country portal under “Working for Helsinn”. Any other sources of communications are unauthorized, and we discourage candidates from replying to suspect employment offers received through unofficial channels. If you are experiencing problems or have questions, please contact: Switzerland: info-HHC@helsinn.com, U.S.: HTU-HR@helsinn.com, Ireland: info-hbp@helsinn.com. [These emails are NOT an application channel: CVs and sensitive information sent inappropriately to the above emails will NOT be considered or processed, and will be DELETED]